Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Armodafinil - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Armodafinil - Teva Pharmaceutical Industries

Alternative Names: CEP-10953; Nuvigil; R-modafinil

Latest Information Update: 17 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon
  • Developer Cephalon; Lindner Center of HOPE; Oncotherapeutics.; Teva Pharmaceutical Industries
  • Class Acetamides; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Biogenic amine receptor agonists; Catecholamine receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia
  • Phase III Eating disorders
  • Discontinued Bipolar depression; Fatigue; Schizophrenia

Most Recent Events

  • 09 Jan 2025 Armodafinil licensed to Miravu healthcare (Nuvo Pharmaceuticals) in the USA
  • 01 Dec 2024 Neuraxpharm acquires Armodafinil
  • 04 Jan 2024 Discontinued - Phase-III for Fatigue in USA (PO) (NDR batch #30)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top